BNTX
Income statement / Annual
Last year (2023), BioNTech SE's total revenue was $3.82 B,
a decrease of 77.94% from the previous year.
In 2023, BioNTech SE's net income was $930.30 M.
See BioNTech SE’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$3.82 B
|
$17.31 B
|
$18.98 B
|
$482.33 M
|
$108.59 M
|
$127.58 M
|
$61.60 M
|
| Cost of Revenue |
$599.80 M |
$4.53 B |
$3.86 B |
$704.36 M |
$243.83 M |
$156.73 M |
$94.81 M |
| Gross Profit |
$3.22 B |
$12.78 B |
$15.12 B |
-$222.04 M |
-$135.24 M |
-$29.16 M |
-$33.22 M |
| Gross Profit Ratio |
0.84 |
0.74 |
0.8 |
-0.46 |
-1.25 |
-0.23 |
-0.54 |
| Research and Development
Expenses |
$1.78 B
|
$116.00 M
|
$102.70 M
|
$645.03 M
|
$226.47 M
|
$143.04 M
|
$85.50 M
|
| General & Administrative
Expenses |
$495.00 M
|
$484.70 M
|
$278.50 M
|
$94.05 M
|
$40.69 M
|
$24.05 M
|
$22.89 M
|
| Selling & Marketing
Expenses |
$62.70 M
|
$59.50 M
|
$50.40 M
|
$14.51 M
|
$2.72 M
|
$3.04 M
|
$6.60 M
|
| Selling, General &
Administrative Expenses |
$557.70 M
|
$544.20 M
|
$328.90 M
|
$108.56 M
|
$43.41 M
|
$27.09 M
|
$29.49 M
|
| Other Expenses |
$188.00 M |
-$524.30 M |
-$128.80 M |
-$893.21 M |
-$223.60 M |
$0.00 |
$0.00 |
| Operating Expenses |
$2.53 B |
$135.90 M |
$200.10 M |
-$139.62 M |
$46.28 M |
$24.70 M |
$28.06 M |
| Cost And Expenses |
$3.13 B |
$4.67 B |
$4.06 B |
$564.74 M |
$290.11 M |
$181.43 M |
$122.88 M |
| Interest Income |
$357.60 M |
$330.30 M |
$1.50 M |
$1.56 M |
$1.78 M |
$2.00 M |
$2.13 M |
| Interest Expense |
$7.90 M |
$18.90 M |
$5.40 M |
$64.95 M |
$1.72 M |
$1.72 M |
$676,000.00 |
| Depreciation &
Amortization |
$183.40 M
|
$121.08 M
|
$78.20 M
|
$36.10 M
|
$33.80 M
|
$22.69 M
|
$9.85 M
|
| EBITDA |
$1.09 B
|
$12.43 B
|
$15.00 B
|
-$105.10 M
|
-$152.30 M
|
-$30.01 M
|
-$48.75 M
|
| EBITDA Ratio |
0.28 |
0.76 |
0.79 |
-0.09 |
-1.35 |
-0.24 |
-0.79 |
| Operating Income Ratio
|
0.18
|
0.73
|
0.81
|
-0.17
|
-1.67
|
-0.42
|
-0.99
|
| Total Other
Income/Expenses Net |
$495.70 M
|
$311.40 M
|
-$237.40 M
|
-$63.40 M
|
$2.10 M
|
$6.19 M
|
-$24.63 M
|
| Income Before Tax |
$1.19 B |
$12.95 B |
$15.05 B |
-$145.80 M |
-$179.44 M |
-$47.66 M |
-$85.91 M |
| Income Before Tax Ratio
|
0.31
|
0.75
|
0.79
|
-0.3
|
-1.65
|
-0.37
|
-1.39
|
| Income Tax Expense |
$255.80 M |
$3.52 B |
$4.75 B |
-$161.00 M |
-$268,000.00 |
$600,000.00 |
$45,000.00 |
| Net Income |
$930.30 M |
$9.43 B |
$10.29 B |
$15.20 M |
-$179.17 M |
-$48.02 M |
-$85.65 M |
| Net Income Ratio |
0.24 |
0.55 |
0.54 |
0.03 |
-1.65 |
-0.38 |
-1.39 |
| EPS |
3.83 |
38.08 |
43.87 |
0.0602 |
-0.85 |
-0.21 |
-0.38 |
| EPS Diluted |
3.83 |
37.09 |
41.21 |
0.057 |
-0.85 |
-0.21 |
-0.38 |
| Weighted Average Shares
Out |
$242.90 M
|
$243.30 M
|
$244.00 M
|
$235.44 M
|
$211.50 M
|
$226.86 M
|
$226.86 M
|
| Weighted Average Shares
Out Diluted |
$242.70 M
|
$249.80 M
|
$259.70 M
|
$248.53 M
|
$211.50 M
|
$226.86 M
|
$226.86 M
|
| Link |
|
|
|
|
|
|
|
